<DOC>
	<DOCNO>NCT02927314</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled clinical trial subject NAFLD NASH .</brief_summary>
	<brief_title>A Study Efficacy Safety CF102 Treatment Non-Alcoholic Fatty Liver Disease</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled study subject diagnosis NAFLD . Subjects undergo Screening procedure 4 week precede Baseline . Subjects randomly assign 1:1:1 ratio oral dos CF102 12.5 mg BID , CF102 25 mg BID , match placebo BID 12 week use stratified randomization , stratification presence absence diabetes mellitus . Subjects evaluate regularly safety , indicator efficacy measure Baseline Week 12 . Subjects return follow-up visit 4 week completion last dose study drug .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . At least 18 year age . 2 . Diagnosis NAFLD noninvasive determination liver triglyceride concentration , define triglyceride concentration ≥10.0 % NMRS . 3 . At least 2 follow : Obesity , define body mass index ( BMI ) ≥25 ≤40 kg/m2 ; waist circumference &gt; 88 &lt; 200 cm woman &gt; 102 &lt; 200 cm men Type II diabetes mellitus , define criterion American Diabetes Association ( Appendix 1 ) Blood pressure 130/85 high ( either systolic diastolic ) Hypertriglyceridemia , define &gt; 150 mg/dL ( &gt; 1.7 mmol/L ) Reduced highdensity lipoprotein ( HDL ) cholesterol , define &lt; 40 mg/dL ( &lt; 1.04 mmol/L ) men &lt; 50 mg/dL ( &lt; 1.3 mmol/L ) woman . 4 . Acceptable hepatic metabolic synthetic function , indicate Screening : Serum albumin ≥3.5 gm/dL INR ≤1.2 Serum total bilirubin ≤2.0 mg/dL . 5 . Absence cirrhosis , define Fibroscan score ≤F4 liver stiffness measurement ( LSM ) 7 13 kPa . 6 . The following laboratory value must document Screening prior initiation study drug : Absolute neutrophil count &gt; 1.5x109/L Platelet count &gt; 100x109/L Serum creatinine &lt; 2.0 mg/dL . 7 . For woman childbearing potential , negative serum pregnancy test result ( pregnant lactating ) . 8 . Understand provide write informed consent participate . 9 . Patients take herbal supplement , homeopathic medication , alternative treatment , must stable regimen least 6 month prior randomization . 10 . Willing comply schedule visit , treatment plan , laboratory assessment , studyrelated procedure . 1 . Presence ascites , hepatic encephalopathy , clinical evidence cirrhosis . 2 . Other active acute chronic liver disease , autoimmune hepatitis , hepatitis B , hepatitis C , alcoholic liver disease , hepatocellular carcinoma time Screening randomization . 3 . Familial dyslipidemia . 4 . Weight loss &gt; 5 % within 6 month prior Baseline . 5 . History bariatric surgery within 5 year Screening . 6 . Diabetes mellitus Type II . 7 . Daily alcohol intake &gt; 20 g/day woman 30 g/day men ( average per day ) , per medical history . 8 . Treatment follow antidiabetic medication : DPP4 inhibitor unless stop 3 month Screening , GLP1 receptor agonist ( Januvia [ sitagliptin ] , Byetta [ incretin ] , etc . ) unless start least 12 month stable dose least 3 month prior Screening . 9 . Metformin , fibrates , statin , insulin , sulfonylurea unless dose stabilize last 1 month prior Screening . 10 . More 7 day treatment valproic acid , tamoxifen , methotrexate , amiodarone , rifaximin , antibiotic , anticholinergic agent within 3 month prior Screening . 11 . Uncontrolled clinically unstable thyroid disease , judgment Principal Investigator . 12 . Seropositivity marker viral hepatitis human immunodeficiency virus ( HIV ) Screening . 13 . Uncontrolled arterial hypertension congestive heart failure ( New York Heart Association Classification 3 4 ) . 14 . Angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation study drug . 15 . History ongoing cardiac dysrhythmias require treatment , atrial fibrillation grade , persistent prolongation QTc ( Fridericia ) interval &gt; 450 msec male &gt; 470 msec female . 16 . Pregnant lactate female . 17 . Women childbearing potential , unless agree use dual contraceptive method , opinion Principal Investigator , effective adequate patient 's circumstance study drug . 18 . Men partner woman childbearing potential , unless agree use effective , dual contraceptive method ( ie , condom , female partner use oral , injectable , barrier method ) study drug . 19 . Any severe , acute , chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere informed consent process and/or compliance requirement study , may interfere interpretation study result , investigator 's opinion , would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>